Go to:
Logótipo
You are here: Start > Publications > View > Comparative Investigation of the Chemiluminescent Properties of a Dibrominated Coelenterazine Analog
Perdidos e Achados - Destaque
Publication

Comparative Investigation of the Chemiluminescent Properties of a Dibrominated Coelenterazine Analog

Title
Comparative Investigation of the Chemiluminescent Properties of a Dibrominated Coelenterazine Analog
Type
Article in International Scientific Journal
Year
2022-07-30
Authors
João Sousa
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Carla M. Magalhães
(Author)
FCUP
Patricia González-Berdullas
(Author)
FCUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications Without AUTHENTICUS Without ORCID
Joaquim C G E Esteves da Silva
(Author)
FCUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Vol. 23
Pages: 8490-8490
ISSN: 1661-6596
Publisher: MDPI
Other information
Authenticus ID: P-00W-ZMS
Abstract (EN): Chemi- and bioluminescence are remarkable light-emitting phenomena, in which thermal energy is converted into excitation energy due to a (bio)chemical reaction. Among a wide variety of chemi-/bioluminescent systems, one of the most well-known and studied systems is that of marine imidazopyrazinones, such as Coelenterazine and Cypridina luciferin. Due to the increasing usefulness of their chemi-/bioluminescent reactions in terms of imaging and sensing applications, among others, significant effort has been made over the years by researchers to develop new derivatives with enhanced properties. Herein, we report the synthesis and chemiluminescent characterization of a novel dibrominated Coelenterazine analog. This novel compound consistently showed superior luminescence, in terms of total light output and emission lifetime, to natural imidazopyrazinones and commercially available analogs in aprotic media, while being capable of yellow light emission. Finally, this new compound showed enhanced chemiluminescence in an aqueous solution when triggered by superoxide anion, showing potential to be used as a basis for optimized probes for reactive oxygen species. In conclusion, bromination of the imidazopyrazinone scaffold appears to be a suitable strategy for obtaining Coelenterazines with enhanced properties.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 13
Documents
File name Description Size
ijms-23-08490-v2 1521.73 KB
Related Publications

Of the same journal

Vanadium Compounds with Antidiabetic Potential (2023)
Another Publication in an International Scientific Journal
Amaral, LMPF; Moniz, T; Silva, AMN; Maria Rangel
Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis (2019)
Another Publication in an International Scientific Journal
Ferreira, N; Maria Joao Saraiva; Almeida, MR
Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems (2019)
Another Publication in an International Scientific Journal
Souto, EB; Dias Ferreira, J; Oliveira, J; Sanchez Lopez, E; Lopez Machado, A; Espina, M; Garcia, ML; Souto, SB; Martins Gomes, C; Silva, AM
Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review (2024)
Another Publication in an International Scientific Journal
Coimbra, S; Rocha, S; Sousa, NR; Cristina Catarino; Belo, L; Bronze da Rocha, E; Valente, MJ; Santos-Silva, A
Therapeutic Approaches for Age-Related Macular Degeneration (2022)
Another Publication in an International Scientific Journal
Galindo-Camacho, RM; Blanco-Llamero, C; da Ana, R; Fuertes, MA; Senorans, FJ; Silva, AM; Garcia, ML; Souto, EB

See all (282)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Engenharia da Universidade do Porto  I Terms and Conditions  I Accessibility  I Index A-Z  I Guest Book
Page generated on: 2025-06-25 at 07:21:53 | Acceptable Use Policy | Data Protection Policy | Complaint Portal